Location: United States
The small, implantable device provides accurate, real-time glucose monitoring for up to 90 days.
Worldwide, 422 million people have diabetes, according to the World Health Organisation. That’s about 1 in every 11 people suffering from a chronic illness that led to 1.5 million deaths and 3.7 million deaths related to high blood sugar in 2016 – A common condition that can benefit from innovative options. Eversense CGM, the world’s first implantable continuous glucose monitor, is using technology to offer diabetics more freedom with their monitoring.
The sensor is less than 2cm long, so requires only a small procedure for the device to be placed just under the skin. Once inserted, the sensor works by connecting to a transmitter on the arm, which is rechargeable and water-resistant. Unlike other CGM devices, the transmitter can be taken off at any time for people who may not want their device on display during certain activities and events.
The device transmits blood sugar readings every five minutes to the Eversense mobile app so that users can get an accurate reading at any time. It displays easy to understand graphs which make it easier for diabetics to track how meals and exercise affect their control.
The transmitter can also vibrate if the blood sugar is too low or too high, providing an instant alert even when it’s not connected to a smartphone. Currently, the implantable device will need to be replaced every 90 days, but a 180-day version is being tested.